Patents Assigned to TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM
  • Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
    Patent number: 11826402
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 28, 2023
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsm
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Method for cellular RNA expression
    Patent number: 10729784
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 4, 2020
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste
  • Method for cellular RNA expression
    Patent number: 10207009
    Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 19, 2019
    Assignees: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSM, BIONTECH RNA PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz, Lars Koste